Project Grant R01HL178085
Award Date 9/1/25
Completion Date 5/31/30
Dollars Obligated $723K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
- This Project Grant award of $389,754 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to assess the therapeutic potential of a peptide derived from collagen XVIII for treating lung fibrosis associated with systemic sclerosis (scleroderma). The project aims to evaluate the anti-fibrotic effects of this peptide in a murine model of lung fibrosis, as well as identify the minimal effective dose, optimal...
- The National Heart, Lung, and Blood Institute (NHLBI), via the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $564,445 Project Grant to the University of Texas Health Science Center at Houston (UTHealth) to fund research on "Targeting Hypoxia-Inducible Factors (HIFs) for Heart and Lung Disease." The 6-year grant, starting on March 1, 2025 and ending on December 31, 2031, supports three complementary research projects focused on investigating the upstream regulation...
- The National Heart, Lung, and Blood Institute (NHLBI), through the Cardiovascular Diseases Research federal grant program (CFDA 93.837), awarded a $188,892 Project Grant to the University of Washington to support research on the role of CD163+ blood monocytes and lung macrophages in progressive pulmonary fibrosis. This 5-year grant, starting August 1, 2025, will fund a physician-scientist's research plan that leverages the university's expertise in immunology, bioinformatics, and lung biology to...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $1,498,380 to Yale University to conduct research on the role of mitochondrial DNA and sex differences in scleroderma-associated interstitial lung disease (SSC-ILD). The research aims to elucidate how differential interactions between extracellular mitochondrial DNA and the Toll-like receptor 9 (TLR9) drive sexual dimorphism in SSC-ILD. Key objectives include...
- This federal Project Grant award from the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) provides $693,558 to the University of California, Los Angeles (UCLA) to validate the use of specific circulating biomarkers as functional response indicators for patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). The research aims to identify reliable early-stage biomarkers that can signal therapeutic efficacy,...
- This federal Project Grant award from the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research program (CFDA 93.837), provides $107,752 to Duke University to investigate the mechanisms of lung fibrosis. The research aims to evaluate epithelial cell-fibroblast interactions contributing to fibroblast activation through the CTHRC1-TGFβ signaling pathway, in the context of bronchiolitis obliterans and idiopathic pulmonary fibrosis. The 2-year project leverages Duke's...
- This Project Grant award, funded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research on the role of protein S-palmitoylation in TGF-beta signaling and fibrotic lung disease at Duke University. The $165,456 grant awarded on August 15, 2025 will fund a 5-year project to investigate how S-palmitoylation of the TGF-beta receptor regulates its activity and fibrotic pathways, and the potential for targeting related...
- The National Heart Lung and Blood Institute (NHLBI), through its Cardiovascular Diseases Research program (CFDA 93.837), awarded a $172,724 project grant to The Regents of the University of California, San Francisco (UCSF) on February 28, 2025. The grant supports research to investigate the epigenetic signatures and gene regulatory networks driving the trans-differentiation of alveolar type II (AT2) cells into airway-like basal cells under homeostatic conditions and in the context of fibrotic...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $594,583 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Children's Hospital of Philadelphia (CHOP) Research Institute. The grant supports research to investigate the mechanisms regulating the development, expansion, and decline of neonatal lung myofibroblasts and their role in alveologenesis. Key objectives include utilizing a novel murine model to study myofibroblast lineage, characterize...
- This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $771,751 to The University of Texas Southwestern Medical Center to conduct research on the prognostic and predictive impact of telomere length in fibrotic interstitial lung disease. The 5-year project aims to leverage a multicenter cohort of over 4,000 patients to quantify how leukocyte telomere length can inform individual progression and mortality risk, as...